---
title: "Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294952732.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-05T10:34:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294952732.md)
  - [en](https://longbridge.com/en/news/294952732.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294952732.md)
---

# Evexta Bio and Roche plan Phase Ib trial of rupitasertib with giredestrant

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [RHHBY.US](https://longbridge.com/en/quote/RHHBY.US.md)
- [RHHVF.US](https://longbridge.com/en/quote/RHHVF.US.md)

## Related News & Research

- [Roche (SWX:ROG) Stock Margin Expansion To 19.6% Tests Bullish Earnings Narratives](https://longbridge.com/en/news/293799255.md)
- [Roche (SWX:ROP) Wins Priority Review For Gazyva And Launches First Automated HDV Test](https://longbridge.com/en/news/292817546.md)
- [BioMarin spends up to $490m for Alesta’s bone disease candidate](https://longbridge.com/en/news/296381315.md)
- [Fulcrum and Slate Medicines sign merger agreement](https://longbridge.com/en/news/296206650.md)
- [Immunology specialist Khartis Therapeutics emerges from stealth with $95m](https://longbridge.com/en/news/295919132.md)